Procter & Gamble’s Pharmaceuticals and Personal Health

Mark A. Collar is currently a venture partner at Triathlon Medical Ventures, a life science focused venture capital firm with over $100 million under management. Mr. Collar was previously President, Global Pharmaceuticals & Personal Health, The Procter & Gamble Company until July 1, 2007, when he announced his intention to retire on January 2, 2008.

Mr. Collar was named President of the Global Pharmaceuticals business in October, 2002, and assumed the additional responsibility for the Global Personal Health business in August, 2005. He had served as Vice President, Global Pharmaceuticals since July, 1997, and has had responsibility for the Pharmaceuticals business since 1994.

Mr. Collar served over 30 years at P&G, starting out carrying a bag as a sales rep on the streets of Chicago. Over the years, Mark held positions of increased responsibility for Procter & Gamble within the Health & Personal Care, Beauty Care, New Business Development, Pharmaceuticals, and Personal Health Care Products divisions. He ended his P&G career as the president of P&G’s health care business. He grew the division from its relatively small origins to over a $4 billion enterprise when he retired.

Mr. Collar resides with his family in Cincinnati, Ohio and holds a Bachelor’s degree from Northern Illinois University.

Ken Phelps
President and CEO  
Camargo Pharmaceutical Services

Mr. Phelps has more than 30 years of experience in the health science and services industry. He began his career synthesizing, characterizing and performing drug metabolism studies of potential carcinogens with the Eppley Center for Research in Cancer. Turning his focus to medical devices, he established a laboratory and started up the manufacturing of sterile blood collection tubes.

Mr. Phelps then joined Merrell National Labs (which evolved into SAnofi-Aventis) directing a group developing new test methods, then as head of the several multi-national quality control laboratories. With the merger into Merrell Dow he assumed global responsibility for quality assurance, quality control and processing technology with an assignment based in Milan, Italy. Later he directed IT for multi-national manufacturing operations leading technical improvements across R&D, Accounting and Manufacturing Operations and integration of technologies with Dow Chemical.

Utilizing this broad background, he joined Duramed Pharmaceuticals (now Barr Pharmaceuticals) with executive-level assignments in quality control, regulatory, project management and clinical and medical affairs where he served as a liaison to sales & marketing.

Mr. Phelps has a BS in Chemistry from the University of Nebraska.

Greg Flexter
President
Blue Ash Therapeutics, LLC

Greg Flexter is President and CEO of Cincinnati-based Blue Ash Therapeutics, a specialist-focused cardiovascular pharmaceutical company. In coming to Blue Ash in 2009 Greg has brought three decades of hands-on experience in pharmaceuticals, from product development to clinical research to business development, general management and executive oversight of both domestic and international operations. In his current role he is responsible for the strategic formation, development, funding and growth of the company in collaboration with a veteran scientist Co-Founder, Dr. Kevin Malloy.

Most recently Greg was President, CEO and Executive Board Member of Newport Kentucky’s Xanodyne Pharmaceuticals with responsibility for leading company strategy and ensuring commercial performance. Mr. Flexter also served over five years with Shire Pharmaceuticals, where he was the Executive VP and General Manager of Shire’s North American operations where he directed and oversaw the growth of the ADHD franchise from $240 million annually in 2001 to over $1 billion in 2005, with portfolio sales of $1.35 billion and contribution of 88% of Shire global revenue.

His coming to Blue Ash Therapeutics, cardiovascular company, is a return to the area in which he began his career at Marion Laboratories in Cardiovascular Clinical Research. In subsequent years Greg broadened his expertise to neuroscience, serving as head of Global Marketing and Medical Research for Neuroscience at Hoechst Marion Roussel and as Vice President and GM of a newly created Neuroscience Business Unit of Novartis Pharmaceuticals, responsible for US Marketing, Sales and Medical Research.

In a career marked with innovation and new product ideas, Mr. Flexter has led over fifteen successful product launches, both domestic and international. He has extensive experience in mergers & acquisitions and business development, and has also consulted with top Venture Capital firms on portfolio company strategy, business performance turn-around and strategic acquisitions.

Thomas P. Jennings, Esq.
General Councel, Corporate Secretary and Chief Regulatory Officer
Xanodyne Pahrmaceuticals, Inc.

Mr. Thomas P. Jennings brings a strategic and growth oriented approach to building branded niche pharmaceutical companies such as Xanodyne Pharmaceuticals, Inc., where he currently serves as General Counsel, Corporate Secretary and Chief Regulatory Officer.

Mr. Jennings was most recently with PediaMed Pharmaceuticals, Inc., where his past experience with emerging pharmaceutical companies served him well in his role as President.

Before joining PediaMed, Mr. Jennings was President of Union Springs, LLC and assisted the Chairman and key investors in founding PediaMed as well as sister companies Integrity Pharmaceutical Corporation and Xanodyne Pharmacal, Inc. His role in all of the companies has been to help establish the strategic vision of the companies, provide business development and legal assistance, and liaison with the Board of Directors and investors. Mr. Jennings also served as Corporate Secretary for each of the Union Springs, LLC companies.

Prior to joining Union Springs, LLC, Mr. Jennings was in private law practice where the primary focus was mergers and acquisitions, and tax related issues. Prior to that, he was a CPA with Ernst & Young.

Mr. Jennings is a graduate of the Salmon P. Chase College of Law and also holds a B.B.A. in Accounting from the University of Cincinnati.

Doug Ladd
Director of Market Development Franchise Development
Ethicon Endo-Surgery

Doug has more than 20 years of business experience in the health care marketing field. He began his career in the pharmaceutical industry with Merrell Dow Pharmaceuticals, later known as Marion Merrell Dow and now part of Aventis. He then worked as a Product Manager and New Business Development Director for ChoiceCare, a not-for-profit HMO subsequently acquired by Humana.

For the past 13 years, Doug has been focused on the medical device industry. He served as VP of Marketing and Sales for AtriCure, Inc. (a venture-backed start-up in the cardiac surgery market that has subsequently gone public) and played an instrumental role in building the company.

His current role is as Director, Marketing for World-Wide Franchise Developmentin Ethicon Endo-Surgery, Inc., a Johnson & Johnson company based in Cincinnati, Ohio. Previously he has worked in new product development marketing as well as brand management with responsibilities in the fields of general surgery, breast care, cardiac surgery and flexible endoscopy.

Ellen Banks
Licensing Associate
University of Cincinnati

Ellen Banks currently serves as a Licensing Associate in the Intellectual Property Office at the University of Cincinnati (“UC”). She is responsible for managing all aspects of academic technology transfer for patents within the life science and physical science portfolios. Ellen also is responsible for preparing and negotiating agreements pertaining to research, licensing, and other aspects of faculty/industry collaborations.

Prior to joining UC, Ellen practiced law for seven years. Most recently, she served as the Assistant General Counsel at Hampton University where she managed all technology transfer operations, including evaluation of major technology innovations, patent prosecution, and commercialization efforts. She also advised senior administrators and faculty members on a range of legal matters surrounding intellectual property, research grants, private/government contracts, federal, state, and local regulations, and university bylaws.

Before specializing in technology transfer within a university setting, Ellen was an associate in the Corporate and Business sections of Williams Mullen, a law firm primarily based in the southeastern part of the nation which employs approximately 300 attorneys. As an associate, Ellen interacted with business clients to handle various corporate legal matters. She has prepared governing documents addressing corporate relations and activities, including employment, service, confidentiality, software, licensing, credit, and financial agreements, as well as copyright applications, publishing contracts, and Web site user agreements.

Ellen received her Bachelor of Arts from the College of William and Mary (Virginia) and Juris Doctorate from the Wake Forest School of Law (North Carolina).